Putting Patients First Blog

JULY 2, 2024

As noted in our previous communications, while the NHC would prefer a more traditional Notice and Comment rulemaking opportunity that would ensure the Agency directly responds to stakeholder feedback, we welcome this opportunity to express our reactions to CMS’ thinking on the negotiation program.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

JUNE 26, 2025

Even well-intentioned policies can create access disparities if communication and operational support are lacking. It is unclear how CMS will communicate this determination or whether stakeholders will be notified and invited to contribute evidence before a new price is set.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98

PharmaShots

FEBRUARY 22, 2023

Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.

Diabetes 64

Diabetes Compounding Dosage Communication 64

Putting Patients First Blog

JANUARY 10, 2024

Failure to Reconcile (FTR) Process: The NHC views the proposed changes to the FTR process positively as safeguarding consumers’ health coverage access, particularly for those with chronic conditions, by enhancing education, aligning with consumer protection principles, and ensuring clarity and accessibility in communication strategies.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Communication Documentation Diabetes 40

Pharmacy Times

JULY 7, 2025

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

Pharmacy Technician 39

Pharmacy Technician Immunity Immunization Compounding Pharmacies 39